HER2-Positive Breast Cancer Treatment Showed Success
A new clinical study found high pathologic complete response rates for patients using T-DXd followed by THP therapy.
Updated on Sept. 29, 2026 in Cancer
The DESTINY-Breast11 study has revealed that a treatment regimen consisting of T-DXd followed by THP resulted in a pathologic complete response for two-thirds of high-risk HER2-positive breast cancer patients. This approach was evaluated for patients with clinical T3 or higher disease, node-positive status, or inflammatory breast cancer.
Why it matters
Identifying effective neoadjuvant treatments for high-risk HER2-positive cancers is crucial for improving patient outcomes before surgery. The study results offer a potential new therapeutic pathway for patients facing challenging, aggressive breast cancer diagnoses.
The DESTINY-Breast11 study reported that two-thirds of participants achieved a pathologic complete response after receiving four cycles of T-DXd followed by four cycles of THP. Rates of response were notably higher in patients with hormone receptor-negative disease.
The players
DESTINY-Breast11
This is a clinical research study investigating neoadjuvant treatment strategies for high-risk HER2-positive early breast cancer.
The details
Researchers compared the T-DXd and THP regimen against a control arm consisting of dose-dense AC followed by THP. The trial focused on high-risk populations, including those with T3 or higher disease, N1 to N3 node-positive status, and inflammatory breast cancer.
Timeline
September 29, 2026: Publication of the DESTINY-Breast11 study findings.
The Big Picture
The DESTINY-Breast11 findings extend the existing clinical standards for treating HER2-positive breast cancer. This research evaluates whether newer targeted therapies can improve upon traditional chemotherapy sequences used in neoadjuvant settings.
This study highlights potential new treatment sequences that may improve response rates for patients facing high-risk HER2-positive breast cancer. Patients should consult with their oncologists to determine how these findings might apply to their specific medical history and therapeutic options.
The takeaway
These findings provide a promising outlook for high-risk patients by demonstrating the efficacy of T-DXd in a neoadjuvant setting. Ongoing follow-up data will be essential for clinicians deciding between this novel regimen and established dose-dense chemotherapy treatments.
Further reading
Learn more about the latest developments in Cancer research and treatments.
